{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:48:46Z","timestamp":1791863326957,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171399"],"award-info":[{"award-number":["82171399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10072-023-07163-3","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T05:06:11Z","timestamp":1698815171000},"page":"1699-1706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Myasthenia gravis and five autoimmune diseases: a bidirectional Mendelian randomization study"],"prefix":"10.1007","volume":"45","author":[{"given":"Kailin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"26","key":"7163_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375(26):2570\u20132581","journal-title":"N Engl J Med"},{"issue":"10","key":"7163_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"key":"7163_CR3","doi-asserted-by":"crossref","unstructured":"Christensen PB et al (1995) Associated autoimmune diseases in myasthenia gravis. Acta Neurol Scand 91(3):192\u2013195","DOI":"10.1111\/j.1600-0404.1995.tb00432.x"},{"issue":"5","key":"7163_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/joim.12310","volume":"277","author":"F Fang","year":"2015","unstructured":"Fang F et al (2015) The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med 277(5):594\u2013604","journal-title":"J Intern Med"},{"issue":"1","key":"7163_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0028-3886.173638","volume":"64","author":"S Tamer","year":"2016","unstructured":"Tamer S et al (2016) Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis. Neurol India 64(1):45\u201349","journal-title":"Neurol India"},{"issue":"6","key":"7163_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","volume":"48","author":"A Nacu","year":"2015","unstructured":"Nacu A et al (2015) Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 48(6):362\u2013368","journal-title":"Autoimmunity"},{"issue":"9","key":"7163_CR7","doi-asserted-by":"publisher","first-page":"e037909","DOI":"10.1136\/bmjopen-2020-037909","volume":"10","author":"JD Green","year":"2020","unstructured":"Green JD et al (2020) Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open 10(9):e037909","journal-title":"BMJ Open"},{"issue":"19","key":"7163_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S (2017) Mendelian randomization. JAMA 318(19):1925\u20131926","journal-title":"JAMA"},{"issue":"10","key":"7163_CR9","doi-asserted-by":"publisher","first-page":"102368","DOI":"10.1016\/j.autrev.2019.102368","volume":"18","author":"RH Song","year":"2019","unstructured":"Song RH et al (2019) Thyroid disorders in patients with myasthenia gravis: a systematic review and meta-analysis. Autoimmun Rev 18(10):102368","journal-title":"Autoimmun Rev"},{"issue":"3","key":"7163_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/00207454.2010.539307","volume":"121","author":"ZF Mao","year":"2011","unstructured":"Mao ZF et al (2011) Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 121(3):121\u2013129","journal-title":"Int J Neurosci"},{"issue":"3","key":"7163_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ane.13254","volume":"142","author":"CC Chou","year":"2020","unstructured":"Chou CC et al (2020) Prevalence and risk of thyroid diseases in myasthenia gravis. Acta Neurol Scand 142(3):239\u2013247","journal-title":"Acta Neurol Scand"},{"issue":"21","key":"7163_CR12","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.1097\/MD.0000000000000835","volume":"94","author":"JH Yeh","year":"2015","unstructured":"Yeh JH et al (2015) Higher risk of myasthenia gravis in patients with thyroid and allergic diseases: a national population-based study. Medicine (Baltimore) 94(21):e835","journal-title":"Medicine (Baltimore)"},{"key":"7163_CR13","doi-asserted-by":"publisher","unstructured":"Chia R, Saez-Atienzar S, Murphy N, Chi\u00f2 A, Blauwendraat C, International Myasthenia Gravis Genomics Consortium, Roda RH, Tienari PJ, Kaminski HJ, Ricciardi R, Guida M, De Rosa A, Petrucci L, Evoli A, Provenzano C, Drachman DB, Traynor BJ (2022) Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A 119(5):e2108672119. https:\/\/doi.org\/10.1073\/pnas.2108672119","DOI":"10.1073\/pnas.2108672119"},{"issue":"4","key":"7163_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J et al (2016) Consistent estimation in Mendelian Randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 40(4):304\u2013314","journal-title":"Genet Epidemiol"},{"issue":"2","key":"7163_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44(2):512\u201325","journal-title":"Int J Epidemiol"},{"issue":"5","key":"7163_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M et al (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50(5):693\u2013698","journal-title":"Nat Genet"},{"issue":"12","key":"7163_CR17","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1468-1331.2007.01978.x","volume":"14","author":"M Kanazawa","year":"2007","unstructured":"Kanazawa M et al (2007) Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur J Neurol 14(12):1403\u20131404","journal-title":"Eur J Neurol"},{"key":"7163_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev-pathol-012513-104713","volume":"9","author":"Y Tomer","year":"2014","unstructured":"Tomer Y (2014) Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol 9:147\u2013156","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"7163_CR19","first-page":"854","volume":"96","author":"C Meng","year":"2016","unstructured":"Meng C et al (2016) Clinical features of myasthenia gravis with thyroid disease with 106 patients. Zhonghua Yi Xue Za Zhi 96(11):854\u2013858","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"3","key":"7163_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1590\/S0004-282X1984000300006","volume":"42","author":"JL De Assis","year":"1984","unstructured":"De Assis JL et al (1984) Thyroid diseases and myasthenia gravis. Arq Neuropsiquiatr 42(3):226\u2013231","journal-title":"Arq Neuropsiquiatr"},{"key":"7163_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fendo.2017.00169","volume":"8","author":"A Lopomo","year":"2017","unstructured":"Lopomo A, Berrih-Aknin S (2017) Autoimmune thyroiditis and myasthenia gravis. Front Endocrinol (Lausanne) 8:169","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"7163_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","volume":"12","author":"S Berrih-Aknin","year":"2013","unstructured":"Berrih-Aknin S et al (2013) Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 12(9):885\u2013893","journal-title":"Autoimmun Rev"},{"issue":"2","key":"7163_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","volume":"14","author":"A Antonelli","year":"2015","unstructured":"Antonelli A et al (2015) Autoimmune thyroid disorders. Autoimmun Rev 14(2):174\u2013180","journal-title":"Autoimmun Rev"},{"key":"7163_CR24","doi-asserted-by":"publisher","first-page":"986789","DOI":"10.1155\/2013\/986789","volume":"2013","author":"SK Bedoya","year":"2013","unstructured":"Bedoya SK et al (2013) Th17 cells in immunity and autoimmunity. Clin Dev Immunol 2013:986789","journal-title":"Clin Dev Immunol"},{"issue":"10 Suppl 4","key":"7163_CR25","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","volume":"5","author":"A Marx","year":"2010","unstructured":"Marx A et al (2010) The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 5(10 Suppl 4):S266\u2013S272","journal-title":"J Thorac Oncol"},{"issue":"6","key":"7163_CR26","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1210\/en.2008-1690","volume":"150","author":"AV Misharin","year":"2009","unstructured":"Misharin AV et al (2009) Studies in mice deficient for the autoimmune regulator (Aire) and transgenic for the thyrotropin receptor reveal a role for Aire in tolerance for thyroid autoantigens. Endocrinology 150(6):2948\u20132956","journal-title":"Endocrinology"},{"key":"7163_CR27","doi-asserted-by":"publisher","first-page":"902658","DOI":"10.3389\/fimmu.2022.902658","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X et al (2022) Clinical application of transcranial magnetic stimulation in multiple sclerosis. Front Immunol 13:902658","journal-title":"Front Immunol"},{"key":"7163_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.msard.2019.06.027","volume":"34","author":"S Dehbashi","year":"2019","unstructured":"Dehbashi S, Hamouda D, Shanina E (2019) Co-occurrence of multiple sclerosis and myasthenia gravis: a case report and review of immunological theories. Mult Scler Relat Disord 34:135\u2013136","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"7163_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","volume":"14","author":"KM Danikowski","year":"2017","unstructured":"Danikowski KM, Jayaraman S, Prabhakar BS (2017) Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation 14(1):117","journal-title":"J Neuroinflammation"},{"issue":"3","key":"7163_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10753-012-9573-z","volume":"36","author":"J Lu","year":"2013","unstructured":"Lu J et al (2013) Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis. Inflammation 36(3):521\u2013528","journal-title":"Inflammation"},{"issue":"12","key":"7163_CR31","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jama.2022.0786","volume":"327","author":"MH Smith","year":"2022","unstructured":"Smith MH, Berman JR (2022) What is rheumatoid arthritis? JAMA 327(12):1194","journal-title":"JAMA"},{"issue":"4","key":"7163_CR32","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10067-022-06062-w","volume":"41","author":"R Bixio","year":"2022","unstructured":"Bixio R et al (2022) Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. Clin Rheumatol 41(4):1247\u20131254","journal-title":"Clin Rheumatol"},{"key":"7163_CR33","doi-asserted-by":"publisher","first-page":"839075","DOI":"10.3389\/fimmu.2022.839075","volume":"13","author":"L Di","year":"2022","unstructured":"Di L et al (2022) A randomized open-labeled trial of methotrexate as a steroid-sparing agent for patients with generalized myasthenia gravis. Front Immunol 13:839075","journal-title":"Front Immunol"},{"issue":"3","key":"7163_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"6","key":"7163_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7163_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14656566.2020.1822325","volume":"22","author":"T El Jammal","year":"2021","unstructured":"El Jammal T et al (2021) State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. Expert Opin Pharmacother 22(2):205\u2013218","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"7163_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A et al (2021) Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol 203(3):366\u2013374","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"7163_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3889\/oamjms.2015.096","volume":"3","author":"R Miskovic","year":"2015","unstructured":"Miskovic R et al (2015) Systemic lupus erythematosus and secondary antiphospholipid syndrome after thymectomy for myasthenia gravis - a case report. Open Access Maced J Med Sci 3(3):439\u2013442","journal-title":"Open Access Maced J Med Sci"},{"issue":"7","key":"7163_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s00415-011-6335-z","volume":"259","author":"M Jallouli","year":"2012","unstructured":"Jallouli M et al (2012) The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol 259(7):1290\u20131297","journal-title":"J Neurol"},{"issue":"9","key":"7163_CR40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.20452\/pamw.773","volume":"119","author":"A Hrycek","year":"2009","unstructured":"Hrycek A (2009) Systemic lupus erythematosus and myasthenia gravis. Pol Arch Med Wewn 119(9):582\u2013585","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"7163_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3899\/jrheum.090450","volume":"37","author":"HT Lee","year":"2010","unstructured":"Lee HT et al (2010) Serum BLC\/CXCL13 concentrations and renal expression of CXCL13\/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 37(1):45\u201352","journal-title":"J Rheumatol"},{"issue":"2","key":"7163_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","volume":"108","author":"A Meraouna","year":"2006","unstructured":"Meraouna A et al (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432\u2013440","journal-title":"Blood"},{"key":"7163_CR43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3389\/fimmu.2019.01265","volume":"10","author":"N Lotfi","year":"2019","unstructured":"Lotfi N et al (2019) Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol 10:1265","journal-title":"Front Immunol"},{"issue":"5\u20136","key":"7163_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000365568","volume":"72","author":"CE Bekircan-Kurt","year":"2014","unstructured":"Bekircan-Kurt CE et al (2014) The course of myasthenia gravis with systemic lupus erythematosus. Eur Neurol 72(5\u20136):326\u2013329","journal-title":"Eur Neurol"},{"issue":"9","key":"7163_CR45","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.autrev.2015.05.002","volume":"14","author":"K Kakleas","year":"2015","unstructured":"Kakleas K et al (2015) Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). Autoimmun Rev 14(9):781\u2013797","journal-title":"Autoimmun Rev"},{"issue":"9","key":"7163_CR46","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.humimm.2007.05.009","volume":"68","author":"MK Viken","year":"2007","unstructured":"Viken MK et al (2007) Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. Hum Immunol 68(9):748\u2013755","journal-title":"Hum Immunol"},{"key":"7163_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S (2014) Myasthenia gravis: paradox versus paradigm in autoimmunity. J Autoimmun 52:1\u201328","journal-title":"J Autoimmun"},{"issue":"2","key":"7163_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0404.2006.00649.x","volume":"114","author":"C Toth","year":"2006","unstructured":"Toth C et al (2006) Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand 114(2):124\u2013132","journal-title":"Acta Neurol Scand"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07163-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T05:10:33Z","timestamp":1730437833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07163-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["7163"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07163-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was based on publicly available data. All ethical approvals were obtained by the authors of original GWAS research. The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Informed consents were obtained from all participants of each GWAS.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}